ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck has acquired the Danish biotechnology company Survac from investment firm DTU Innovation for roughly $13 million. Survac has developed a technology to identify and modify peptides that are useful for therapeutic cancer vaccines. The acquisition includes patents in the area of proteins that are essential for the survival of cancer cells and, thus, are ideal targets for cancer treatments, Merck says. Survac is run on a virtual basis in collaboration with European academic institutes and clinics.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter